CLE-901

CLE-901 is a small molecule drug developed by Clexio Biosciences. It acts as an antagonist of the NMDA (N-methyl-D-aspartate) receptor, a subtype of glutamate receptor involved in synaptic plasticity and neurotransmission. The drug is being investigated for its potential to treat nervous system diseases, with a primary focus on bipolar disorder. Preclinical studies suggest that NMDA receptor antagonists like CLE-901 may modulate glutamatergic signaling implicated in mood disorders. There is also evidence from related compounds (such as the closely related pipeline compound CLE-901-M) that these agents can induce antidepressant effects and enhance synaptic plasticity in patient-derived neuronal models[1][2][3][4].